MariTide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
MariTide is Amgen's once a month obesity shot. It turns one appetite signal on (GLP-1) and blocks another (GIP). People lost up to about 20 percent of their weight in a year in a mid-stage study.
Evidence grade for MariTide: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
1 effects reported, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
MariTide is a once a month weight loss shot from Amgen. It turns on one hunger signal, GLP-1, like Ozempic does. At the same time it blocks another one, GIP. Most other new drugs turn GIP on instead. It is not approved. It is in large final-stage studies.
What people take it for
- Weight loss with one shot a month instead of one a week.
- Weight loss with type 2 diabetes.
What studies in people showed
The main study had 592 people and ran a year. People with obesity lost 12 to 16 percent of their weight. People on a dummy shot lost 2.5 percent. Counting only people who stayed on it, the company says up to about 20 percent. People with type 2 diabetes lost about 17 percent by that count. Weight was still falling when the study ended. Two large final-stage studies are running, with results due in 2027.
What people report
Reports, not study results
The good
- In the studies on this page, people lost a lot of weight on one shot a month, and it was still coming off at the end.
The bad
- The studies on this page do not list side effects, and we have not collected user reports on this one yet.
Where these come from: The good line is from the two studies on this page. We have not collected forum or user reports for this drug yet.
My bottom line
One shot a month is a real selling point. But it is not approved, and anything sold online as MariTide is not the drug. Wait for the big studies, and keep lifting.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals MariTide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight592 people · 2 studies
- Blood sugar and insulinno headcount stated · 1 study
34 of the 36 indexed goals have no study of any kind behind MariTide
No study in people, animals or cells on this page reports a result for these. That does not prove MariTide does nothing for them. It does mean anything you have heard about MariTide and one of these did not come from a study cited here.
Show full evidence
What is MariTide?
MariTide is Amgen's once a month obesity shot. It turns one appetite signal on (GLP-1) and blocks another (GIP). People lost up to about 20 percent of their weight in a year in a mid-stage study.
MariTide is an experimental obesity drug from Amgen, given as a shot once a month. It is built in an unusual way. One part turns on the GLP-1 signal, like Ozempic does. The other part is an antibody that blocks the GIP signal. Other leading drugs turn GIP on instead. In a mid-stage study of 592 people, those with obesity lost 12.3 to 16.2 percent of their weight in 52 weeks, counting everyone who started. People on a dummy shot lost 2.5 percent. Counting only people who stayed on it, the company reports up to about 20 percent. Two large final-stage studies, MARITIME-1 and MARITIME-2, are running, with main results expected in 2027. A monthly shot could be easier to live with than a weekly one.
How does MariTide work?
One part turns on the GLP-1 signal, which cuts appetite. The other part blocks the GIP signal. The drug is joined to an antibody, so one shot lasts a month.
The evidence, in charts
Fig. 1a · how many people
592people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| New England Journal of Medicine 2025 | 592 | 100% |
The whole total is one study of 592. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- About 145 kDa: the maridebart antibody component is 144,765 Da (KEGG) and carries two conjugated GLP-1 peptide analogs
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for MariTide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial
A once a month injection produced serious weight loss, and it had not finished working when the trial stopped. 592 people took part. Those with obesity lost between 12 and 16 percent of their weight over a year, against about 2.5 percent on a dummy. The weight curve was still falling at the end, so nobody knows yet where it settles. This is a middle stage trial, not a final one.
592 participants: 12.3% to 16.2% weight loss at 52 weeks in the obesity cohort versus 2.5% with placebo (treatment-policy estimand), with no plateau.
- Study in people2025Results from Amgen's Phase 2 obesity study of monthly MariTide presented at the American Diabetes Association 85th Scientific Sessions
This is the company's own account of its trial, given at a conference. It reports up to about 20 percent weight loss in people with obesity after a year, and about 17 percent in people who also had type 2 diabetes. The figure quoted assumes people stayed on the drug. A full late stage programme has now started, and that is what will decide the question.
Up to about 20% weight loss (efficacy estimand) in obesity and about 17% with type 2 diabetes at 52 weeks; Phase 3 MARITIME program initiated.
Common questions
Has MariTide been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. MariTide is Amgen's once a month obesity shot. It turns one appetite signal on (GLP-1) and blocks another (GIP). People lost up to about 20 percent of their weight in a year in a mid-stage study.
What is the MariTide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is MariTide FDA-approved?
Investigational (in final-stage studies)
Why does MariTide block GIP when other drugs activate it?
Scientists are still arguing about it. Turning GIP on, as tirzepatide does, and blocking it, as MariTide does, can both help weight loss. Studies are testing which way works better.
Latest reading on MariTide
Blog posts about MariTide, newest first.